Dallas, Texas 03/14/2014 (FINANCIALSTRENDS) – Plandai Biotechnology Inc (OTCMKTS:PLPL) will be offering its expertise to draft a legislation which will facilitate and guide legalization of marijuana for medical purposes in South Africa. The company will take services of the South African law firm, Werksmans Attorneys, (LEX Africa) Sandton who also specialize in health law, to help them draft and file comments on the bill. The bill if passed will legalize usage of marijuana for medical purpose and eventually allow companies in the region to conduct medical research on the same. The bill was introduced this February in the South African Assembly and the bill’s primary objective is to set up more research hospitals especially relating the area where treatment and cure of cancer is researched. The bill also legalizes the medical, industrial and commercial use of cannabis in South African. Under the current law, medical practioners are legally denied to prescribe cannabis and other proven harmless and effective medication.
Plandai Biotechnology Inc (OTCMKTS:PLPL) Announces Company’s Vice President.
Plandai Biotechnology announced Jamen Shively as its Vice President. Jamen a former Microsoft executive will be part of Plandai’s Global Marketing. Jamen who became a marijuana entrepreneur after moving from Microsoft has help Diego Pellicer(R) and Phytofare(TM) build their brand names. With Jamen’s expertise on marijuana arena it will certainly be an advantage for Plandai. In his new role, Jamen will focus on building brand awareness and marketing strategy for all of the company’s operations.
Plandaí Biotechnology Acquires 100% Stake In Dunn Roman
Plandaí has announced it has acquired 18% more stake in Dunn Roman Holdings Africa (Pty) Ltd. With this the company owns 100% of Dunn Roman Holdings. According to company’s CEO, the acquisition will logically viable as the company can consolidate South African business and expect generate income from the location.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.financialstrend.com/disclaimer